Tudor Investment Corp’s PMV Pharmaceuticals PMVP Stock Holding History

Tudor Investment Corp’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-85,553	Closed	-$1.02M	–	2749
2022 Q3	$1.02M	Buy	+85,553	New	+$1.24M	0.02%	899

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Tudor Investment Corp's PMVP Position: Q4 2022 in Review

Tudor Investment Corp sold out of PMV Pharmaceuticals (PMVP) in Q4 2022, closing a stake of 85,553 shares — an estimated $1.02M sold.

Tudor Investment Corp first reported a position in PMVP in Q3 2022 and held it in 1 quarter. The position peaked at $1.02M in Q3 2022. 115 funds tracked by Wall St. Rank hold PMVP as of Q4 2022.

Tudor Investment Corp reported no remaining PMV Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Tudor Investment Corp sold 85,553 PMV Pharmaceuticals shares in Q4 2022, an estimated $1.02M.
Tudor Investment Corp first reported a position in PMV Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Tudor Investment Corp's PMV Pharmaceuticals position peaked at $1.02M in Q3 2022.
115 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2022.

Based on Tudor Investment Corp's 13F filing for Q4 2022, filed 14 Feb 2023.